The Current Role of Androgen Deprivation in Patients Undergoing Dose-Escalated External Beam Radiation Therapy for Clinically Localized Prostate Cancer

The Current Role of Androgen Deprivation in Patients Undergoing Dose-Escalated External Beam Radiation Therapy for Clinically Localized Prostate Cancer

Purpose. To review existing literature on the role of androgen deprivation therapy (ADT) with dose escalated radiation therapy. Methods and Materials. A PubMed search was undertaken to identify relevant articles. Results. Multiple recent studies were identified examining the role of ADT in the curre...

Full description

Bibliographic Details
Main Authors:	Michael J. Smith, Naveed H. Akhtar, Scott T. Tagawa
Format:	Article
Language:	English
Published:	Hindawi Limited 2012-01-01
Series:	Prostate Cancer
Online Access:	http://dx.doi.org/10.1155/2012/280278

Similar Items

COMBINED RADIATION THERAPY FOR PROSTATE CANCER WITH DOSE ESCALATION BRACHYTHERAPY AND ANDROGEN DEPRIVATION
by: Auchynikau V. A., et al.
Published: (2018-09-01)

Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy
by: Michelle S. Ludwig MD, MPH, PhD, et al.
Published: (2017-01-01)

External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer
by: Tobin J. Strom, et al.
Published: (2014-08-01)

Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?
by: Shakespeare TP, et al.
Published: (2016-05-01)

Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation
by: Wei-Hsien Hou, et al.
Published: (2017-01-01)

DOSE-ESCALATED EXTERNAL BEAM RADIOTHERAPY DURING HORMONO-RADIOTHERAPY FOR PROSTATE CANCER
by: Yu. V. Gumenetskaya, et al.
Published: (2016-07-01)

Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?
by: Shakespeare TP, et al.
Published: (2016-03-01)

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer
by: Rafael Gadia, MD, et al.
Published: (2016-10-01)

Individualized Dose-Escalation of HDR Prostate Brachytherapy Implant to Decrease Required External Beam Radiation Dose: A Retrospective Feasibility Study
by: Hannah M. Dahn, MD, et al.
Published: (2019-10-01)

Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
by: Daniel N. Cagney, et al.
Published: (2017-08-01)

Dose escalation of external beam radiotherapy for high-risk prostate cancer—Impact of multiple high-risk factor
by: Rei Umezawa, et al.
Published: (2019-04-01)

Radiation therapy and androgen deprivation in the management of high risk prostate cancer
by: Alan Dal Pra, et al.
Published: (2011-04-01)

Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer
by: Wilcox SW, et al.
Published: (2014-08-01)

Efficacy of zoledronic acid in older prostate cancer patients undergoing androgen deprivation therapy
by: Ippei Kojima, et al.
Published: (2019-12-01)

Cognition in prostate cancer patients before undergoing androgen deprivation therapy and elderly males
by: Joshee, Paras
Published: (2018)

Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy
by: Jennifer L. Kalina, et al.
Published: (2017-01-01)

Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
by: Aditya Bagrodia, et al.
Published: (2009-01-01)

Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy.
by: Dongseong Shin, et al.
Published: (2020-01-01)

Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?
by: Sonja Cabarkapa, et al.
Published: (2018-03-01)

The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada
by: Margot K. Davis, et al.
Published: (2015-01-01)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
by: Shtutman Michael, et al.
Published: (2010-04-01)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
by: Shimajiri Shohei, et al.
Published: (2011-05-01)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
by: Giovanni Corona, et al.
Published: (2021-07-01)

Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR)
by: Yeon Joo Kim, et al.
Published: (2020-10-01)

Dietary risk factors for bone loss among men undergoing androgen deprivation therapy for the treatment of prostate cancer
by: Wiens, Kristin Patricia
Published: (2010)

Dietary risk factors for bone loss among men undergoing androgen deprivation therapy for the treatment of prostate cancer
by: Wiens, Kristin Patricia
Published: (2010)

Dietary risk factors for bone loss among men undergoing androgen deprivation therapy for the treatment of prostate cancer
by: Wiens, Kristin Patricia
Published: (2010)

Effects of a Lifestyle Intervention on Change in Body Composition in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
by: Chaplow, Zachary Lewis
Published: (2018)

Predictors of physical activity and quality of life in New Zealand prostate cancer survivors undergoing androgen-deprivation therapy
by: Keogh, JW, et al.
Published: (2011)

Radiation treatment planning with embedded dose escalation
by: William T. Hrinivich, et al.
Published: (2019-08-01)

Rectal dose sparing and prostate immobilization using a rectal balloon in the treatment of prostate cancer with dose escalation conformal radiation therapy
by: Kanyike, Daniel Mukasa
Published: (2008)

Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells.
by: Dominick G A Burton, et al.
Published: (2013-01-01)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
by: Justin H. Hwang, et al.
Published: (2019-11-01)

Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data
by: Emily S. Weg, MD, et al.
Published: (2019-07-01)

Patterns of Dose Escalation Among Patients With Esophageal Cancer Undergoing Definitive Radiation Therapy: 2006-2016
by: Elizabeth R. Zhang-Velten, MD, PhD, et al.
Published: (2021-03-01)

A cost-outcome analysis of androgen deprivation therapy and androgen deprivation therapy combine radiotherapy for locally advanced prostate cancer
by: Wei-Na Wang, et al.
Published: (2011)

Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy
by: Landon Wark, et al.
Published: (2019-08-01)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
by: Rahul Jena
Published: (2020-01-01)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
by: Jui-Ming Liu, et al.
Published: (2020-01-01)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
by: Jen‐Tsan Chi, et al.
Published: (2020-06-01)

Cannot write session to /tmp/vufind_sessions/sess_nm6dv9gj8c589uf0a6fe256rv9